The Pharma & Biotech Patent Litigation Summit, Europe 2024

Join Europe’s Leading Pharmaceutical and Biotech Legal Community to Define, Shape and Create Successful Patent Strategies and Mitigate Risks

Download Your Agenda
Anantara Grand Hotel, Amsterdam
22-24 January, 2024

“Great conference to attend, very relevant topics. It has been a pleasure to be speaker and share views with other in-house counsel from the innovator/generic side and external counsels. The networking opportunities are great.”

Toni Santamaria, Adalvo

Where the IP Industry Comes Together

The Pharma and Biotech Patent Litigation Summit returns to Antantara Grand Hotel for 3 days practical discussion surrounding the leading patent litigation topics in Europe, with a compare and contrast method with jurisdictions further afield. Our internationally recognised summit will provide you with the necessary practical tools to both defend patent litigation challenges for your pharma and biotech product, whilst also maximising your litigation strategy to allow for successful IP protection. With the central case law and regulatory updates, this event is a must-attend for anyone with a focus on the European market and working within life science IP. 

BOOK Your PLACE TODAY 

200+
Attendees
60+
Leading Top Speakers
10+
Jurisdiction-specific Roundtable Discussions

With a full slate of main-stage keynotes, breakout sessions, networking and more across three jam-packed days, you and your team will gain the connections and insights you need across three key pillars.

NEW FOR 2024

This year’s summit will host the cross-industry UPC Litigation Forum 2024 as a one-day meeting on 22nd January. This event will host the leading litigators and patent attorneys, in-house counsel and judges for a practical review of the early-stage experience of the UPC. At this event, you will network with leading figures in the industry and gain unique insights on the latest regulatory changes and case-law updates.  

HIGHLIGHTS FOR 2024

  1. Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
  2. Update your pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
  3. Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
  4. Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC. 

Our 2024 Speakers

 

Andras Kupecz

Honourable Judge
UPC Munich Central Division

Andras Kupecz

Honourable Judge
UPC Munich Central Division

Andras Kupecz

Honourable Judge
UPC Munich Central Division
 

Andreas Robinson

Senior Counsel Intellectual Property & Litigation
Amgen

Andreas Robinson

Senior Counsel Intellectual Property & Litigation
Amgen

Andreas Robinson

Senior Counsel Intellectual Property & Litigation
Amgen
 

Brian O'Moore

Honourable Judge
Irish High Court

Brian O'Moore

Honourable Judge
Irish High Court

Brian O'Moore

Honourable Judge
Irish High Court
 

Conrad Eckhardt

Vice President IP
Biotronik

Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.

Conrad Eckhardt

Vice President IP
Biotronik

Conrad Eckhardt

Vice President IP
Biotronik

Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.

 

Edgar Brinkman

Honourable Judge
UPC Local Division Hague

Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).

Edgar Brinkman

Honourable Judge
UPC Local Division Hague

Edgar Brinkman

Honourable Judge
UPC Local Division Hague

Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).

 

Eun-Joo Min

Director
WIPO Judicial Institute

Eun-Joo Min

Director
WIPO Judicial Institute

Eun-Joo Min

Director
WIPO Judicial Institute
 

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
 

Filipe Pedro

Director of IP
BIAL

Filipe Pedro

Director of IP
BIAL

Filipe Pedro

Director of IP
BIAL
 

Filip De Corte

Head of IP
Syngenta

Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D.

Filip De Corte

Head of IP
Syngenta

Filip De Corte

Head of IP
Syngenta

Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management.  Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.

 

Frank Landolt

Chief Counsel IP & Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

Frank Landolt

Chief Counsel IP & Legal
Confo Therapeutics

Frank Landolt

Chief Counsel IP & Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands. 

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth. 

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.

Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

 

Guido Pontremoli

Coporate IP Patent Director
Chiesi

Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.

 

Guido Pontremoli

Coporate IP Patent Director
Chiesi

Guido Pontremoli

Coporate IP Patent Director
Chiesi

Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.

 

Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.

Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.

 

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France.

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin Pramberger

Intellectual Property Director
Polpharma Group

Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

 

Jiri Slavik

Director of IP
Adalvo

Jiri Slavik

Director of IP
Adalvo

Jiri Slavik

Director of IP
Adalvo
 

Kit Carter

Head of IP Litigation
Sandoz

Kit Carter

Head of IP Litigation
Sandoz

Kit Carter

Head of IP Litigation
Sandoz
 

Kristin Cooklin

Head of IP
Zentiva

Kristin Cooklin

Head of IP
Zentiva

Kristin Cooklin

Head of IP
Zentiva
 

Laetitia Szaller

General Counsel
AM Pharma

Laetitia has over 20 years’ experience in multiple sectors, including 15 in the pharmaceuticals and medical device industry, leading and managing complex multi-jurisdiction operations including global multi-million M&A deals. Prior to joining AM-Pharma in April 2020 as General Counsel, VP Business Development and Corporate Secretary, she was at UCB as global Associate General Counsel BD, M&A and Antitrust.

Laetitia Szaller

General Counsel
AM Pharma

Laetitia Szaller

General Counsel
AM Pharma

Laetitia has over 20 years’ experience in multiple sectors, including 15 in the pharmaceuticals and medical device industry, leading and managing complex multi-jurisdiction operations including global multi-million M&A deals. Prior to joining AM-Pharma in April 2020 as General Counsel, VP Business Development and Corporate Secretary, she was at UCB as global Associate General Counsel BD, M&A and Antitrust. Prior to UCB, Laetitia was Legal Director, Emerging Markets EMEA, Central European Region and  Benelux at Zoetis (Pfizer former   animal   health   division), and has also led the EMEA legal department  for the Abbott Vascular division at Abbott. She also held global positions at the Carlson Rezidor Hotel Group and at the automotive division (Wabco) at American Standard.  Laetitia is a qualified lawyer in both the UK and Belgium, with extensive international experience, regularly speaking at various legal conferences.

 

Marc Holtorf

Partner
Pinsent Masons

Marc Holtorf

Partner
Pinsent Masons

Marc Holtorf

Partner
Pinsent Masons
 

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

 

Maximilian Haedicke

Honourable Judge
UPC Court of Appeals

Maximilian Haedicke

Honourable Judge
UPC Court of Appeals

Maximilian Haedicke

Honourable Judge
UPC Court of Appeals
 

Patricia Rombach

Honourable Judge
UPC Court of Appeals

Patricia Rombach

Honourable Judge
UPC Court of Appeals

Patricia Rombach

Honourable Judge
UPC Court of Appeals
 

Paul Inman

Partner
Gowling

With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.

 

Paul Inman

Partner
Gowling

Paul Inman

Partner
Gowling

With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.

 

Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.

 

As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.

 

Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.

 

Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.

 

Stefan Luginbuehl

Head of Department European Legal Affairs
European Patent Office (EPO)

Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.

Stefan Luginbuehl

Head of Department European Legal Affairs
European Patent Office (EPO)

Stefan Luginbuehl

Head of Department European Legal Affairs
European Patent Office (EPO)

Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.

He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.

 

Stefan Schilling

Honourable Judge
UPC Local Division Hamburg

Stefan Schilling

Honourable Judge
UPC Local Division Hamburg

Stefan Schilling

Honourable Judge
UPC Local Division Hamburg
 

Stefanie Kies

Senior Director Intellectual Property
Polpharma Biologics

Stefanie Kies

Senior Director Intellectual Property
Polpharma Biologics

Stefanie Kies

Senior Director Intellectual Property
Polpharma Biologics
 

Sufiyah Sulaiman

Senior Patent Manager Patent Litigation
STADA

Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris). 

Sufiyah Sulaiman

Senior Patent Manager Patent Litigation
STADA

Sufiyah Sulaiman

Senior Patent Manager Patent Litigation
STADA

Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris). 

 

Clemens Heusch

Head of Global Disputes and Resolution
Nokia

Clemens Heusch

Head of Global Disputes and Resolution
Nokia

Clemens Heusch

Head of Global Disputes and Resolution
Nokia
 

Toni Santamaria

Vice President Intellectual Property
Adalvo

Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.

Toni Santamaria

Vice President Intellectual Property
Adalvo

Toni Santamaria

Vice President Intellectual Property
Adalvo

Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.

 

Diane Adair

Senior IP Counsel
Novartis

Diane Adair

Senior IP Counsel
Novartis

Diane Adair

Senior IP Counsel
Novartis
 

Petri Rinkenen

Honourable Judge
UPC Helsinki Local Division

Mr. Petri Rinkinen works as a legally qualified judge in the Unified Patent Court (UPC). He is the presiding judge in the Helsinki local division. He has worked as a judge from September 2013 in the exclusive Finnish IP-court, the Market Court in Helsinki, Finland focusing on IPR-matters, especially to patent cases. Prior to joining the court he has worked as an attorney-at-law since mid 1990’s focusing on IPR-matters. He is a frequent lecturer in IPR-matters. 

Petri Rinkenen

Honourable Judge
UPC Helsinki Local Division

Petri Rinkenen

Honourable Judge
UPC Helsinki Local Division

Mr. Petri Rinkinen works as a legally qualified judge in the Unified Patent Court (UPC). He is the presiding judge in the Helsinki local division. He has worked as a judge from September 2013 in the exclusive Finnish IP-court, the Market Court in Helsinki, Finland focusing on IPR-matters, especially to patent cases. Prior to joining the court he has worked as an attorney-at-law since mid 1990’s focusing on IPR-matters. He is a frequent lecturer in IPR-matters. 

Agenda

"The event provided an exceptionally strong palette of issues relevant for practitioners in the pharma/biotech patent litigation field. The panels were of high quality and I particularly appreciated the practical and transparent insights of industry speakers and UPC judges. The venue and logistics were also excellent, a really high quality conference overall." - Danubia Legal

Our conference programme features the latest insights from the industry’s top companies and key thoughts-leaders, tackling the most pertinent issues and trends in the industry.

With three stages of content, you’ll be able to tailor your perfect agenda to meet your specific business needs – allowing you & your team to gain the tangible intel you need to fast-track your product development over the next 12 months.

DOWNLOAD THE AGENDA

 

Our 2024 Partners

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us